Zacks Investment Research
03 Aug 2026, 15:40 UTC · 6w ago
Verdict
Headline leans bullish. We score DGX +0.80 across four claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+0.80strongly bullish
What the story claims
4 claims · scored −1 bearish … +1 bullish
Quest Diagnostics raised its 2026 revenue guidance to a range of $11.95 billion to $12.05 billion and adjusted earnings guidance to $11.05 to $11.25 per share.
More positive than 91% of claims this week
Quest Diagnostics' second-quarter revenues rose 10.2% to $3.04 billion, exceeding consensus estimates by 2.1%.
So whatAn earnings beat demonstrates current operational strength and supports the validity of the raised forward guidance.
Continue reading
5 related stories
More positive than 87% of ticker scores this week
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 77% of claims this week
Organic requisition volume grew 13%, though revenue per requisition declined by 2.8%.
So whatStrong volume growth is positive, but the decline in pricing power suggests a slight headwind to margins.
More positive than 54% of claims this week
The Corewell Health joint venture is expected to contribute approximately $250 million to 2026 revenues.
So whatWhile contributing to growth, the text notes that such acquisitions and partnerships may come with lower margins.
More positive than 45% of claims this week
Which stocks this story touches
More positive than 87% of ticker scores this week
Raised 2026 revenue and earnings guidance after second-quarter results topped expectations.
More negative than 71% of ticker scores this week
Mentioned as a competitor facing a peer (DGX) that is currently seeing strong growth and expanding market share.
More negative than 68% of ticker scores this week
Mentioned as operating in the kidney-care ecosystem that Quest Diagnostics is now targeting for growth.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
5h ago
More positive than 15% of relationship scores this week
[mutual] DaVita operates in the same broader kidney-health ecosystem that Quest is targeting.
+6.2%
Price agrees with the score
$247.45 vs $233.01 close before publication (Jul 31) · not market-adjusted
DGX chart →
